AXA has committed $300M to a health initiative, managed by AXA Investment Managers and designed to facilitate access to healthcare for underserved populations in emerging and mature markets. This initiative will support, amongst other global health issues, treatment of women’s specific health conditions as well as infectious diseases, vision and diabetes/obesity related conditions. The strategy will be launched in the first quarter of 2022.
AXA is committed to bring leading industry professionals onboard to create an expert global health investment team. Combining the discipline of private equity healthcare investing with a clearly defined purpose and intentionality to address inequalities at a global scale, this investment strategy seeks to build a bridge from high income markets to high volume markets. It will focus on four categories of products: medical devices, biopharmaceuticals, vaccines, and diagnostics. The initiative will target investment opportunities in global health (Diabetes & Obesity, Vision Care & Blindness, Infectious diseases, Maternal & child health, Other conditions with high prevalence in low-income countries).
AXA CEO Thomas Buberl shared: “The pandemic has shown how critical access to quality health solutions is. With this new investment initiative, we aim to make a concrete impact on the lives of undeserved populations by supporting the development of innovative and adapted healthcare solutions. It is another proof of our Purpose to act for human progress by protecting what matters.”